Clinical and Histopathologic Efficiency of Sucralfate and Ursodeoxicolic Acid in Pediatric Duodenogastric Reflux Disease

Year 2023, Volume: 5 Issue: 1, 9 - 14, 15.01.2023

Mehmet Emin Parlak , Atike Atalay , Aygen Yılmaz

https://doi.org/10.37990/medr.1186055

Abstract

Aim: The treatment approach, long-term consequences and surveillance protocols of duodenogastric reflux disease (DGRD) are not well established in the pediatric population. The aim of this study was to evaluate the histopathological and clinical responses to treatment with Ursodeoxicolic Acid (UDCA) and Sucralfate in children diagnosed with DGRD.
Material and Methods: This is a retrospective pre-post design study performed with children admitted to our clinic with reflux symptoms and diagnosed with duodenogastric reflux disease according to endoscopic and histopathologic evaluation. Patients were treated with Sucralfate 60mg/kg/day orally and UDCA at 10 mg/kg/day orally, for 6 months. We compared symptoms/findings, presence of Helicobacter pylori and histopathologic grade of disease before and after treatment.
Results: The presence of all symptoms statistically significantly decreased after treatment. The presence of Helicobacter pylori decreased from 43.8% to 21.9%. There was also statistically significantly histopathologic improvement after six-month treatment of Sucrafate and UDCA.
Conclusion: Six-month treatment of Sucralfate and UDCA provided valuable improvements in clinical and histopathologic features in pediatric patients with DGRD.

Keywords

Duodenogastric Reflux Disease, Sucralfate, Ursodeoxycholic Acid

References

• 1. Zhang Y, Yang X, Gu W, et al. Histological features of the gastric mucosa in children with primary bile reflux gastritis. World J Surg Oncol. 2012;10:27.
• 2. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology. 1995;108:1897-907.
• 3. Szarszewski A, Korzon M, Kamiñska B, et al. Duodenogastric reflux: clinical and therapeutic aspects. Arch Dis Child. 1999;81:16-20.
• 4. Hermans D, Sokal EM, Collard JM, et al. Primary duodenogastric reflux in children and adolescents. Eur J Pediatr. 2003;162:598-602.
• 5. Burden WR, Hodges RP, Hsu M, O'Leary JP. Alkaline reflux gastritis. Surg Clin North Am. 1991;71:33-44.
• 6. Dalenbäck J, Abrahamson H, Björnson E, et al. Human duodenogastric reflux, retroperistalsis, and MMC. Am J Physiol. 1998;275:R762-9.
• 7. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the north american society for pediatric gastroenterology, hepatology, and nutrition and the european society for pediatric gastroenterology, hepatology, and nutrition. Journal Of Pediatric Gastroenterology and Nutrition. 2018;66:516-54.
• 8. Stefaniwsky AB, Tint GS, Speck J, et al. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology. 1985;89:1000-4.
• 9. Rosman AS. Efficacy of UDCA in treating bile reflux gastritis. Gastroenterology. 1987;92:269.
• 10. Neyzi O, Bundak R, Gökçay G, et al. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2015;7:280-93.
• 11. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-81.
• 12. Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392-1413, 413.e1-5.
• 13. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-83.
• 14. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology. 2011;140:e18-52; quiz e13.
• 15. Souza RF. From Reflux Esophagitis to Esophageal Adenocarcinoma. Dig Dis. 2016;34:483-90.
• 16. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44:598-602.
• 17. Peng S, Huo X, Rezaei D, et al. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:G129-39.
• 18. Singh S, Khanna S, Pardi DS, et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:1631-8.
• 19. Chen TF, Yadav PK, Wu RJ, et al. Comparative evaluation of intragastric bile acids and hepatobiliary scintigraphy in the diagnosis of duodenogastric reflux. World J Gastroenterol. 2013;19:2187-96.
• 20. Mittal BR, Ibrarullah M, Agarwal DK, et al. Comparative evaluation of scintigraphy and upper gastrointestinal tract endoscopy for detection of duodenogastric reflux. Ann Nucl Med. 1994;8:183-6.
• 21. Camacho-Gomez SM, Bernieh A, Saad AG, et al. Non-Helicobacter pylori Gastric Intestinal Metaplasia in Children: A Series of Cases and Review of the Literature. Case Rep Gastrointest Med. 2018;2018:5930415.
• 22. Riddell RH. Pathobiology of Helicobacter pylori infection in children. Can J Gastroenterol. 1999;13:599-603.
• 23. Oderda G, Vaira D, Holton J. Age-related increase of Helicobacter pylori frequency in symptom-free and in dyspeptic children. Lancet. 1992;340:671-2.
• 24. Wu TC, Chen LK, Hwang SJ. Seroprevalence of Helicobacter pylori in school-aged Chinese in Taipei City and relationship between ABO blood groups. World J Gastroenterol. 2003;9:1752-5.